SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT OF
FOREIGN ISSUER
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For
the month of April 2005
Commission
File Number 000-51122
pSivida
Limited
(Translation
of registrant’s name into English)
Level 12
BGC Centre
28 The
Esplanade
Perth WA
6000
(Address
of principal executive offices)
(Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F).
Form 20-F
ý Form
40-F o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):
Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o No
ý
If "Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- ___.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant,
pSivida Limited, has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
|
|
|
pSivida
Limited |
|
|
|
Date: April 12,
2005 |
By: |
/s/ Aaron Finlay |
|
Aaron Finlay |
|
Chief Financial Officer and
Company Secretary |
EXHIBIT
INDEX
EXHIBIT
99.1: |
Top
5 Global Pharmaceutical Company: Significant Progress in
BioSiliconTM
Drug
Delivery Evaluation |
|
|